Abstract: The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
July 3, 2018
Assignees:
BIOMARCK PHARMACEUTICALS LTD, NORTH CAROLINA STATE UNIVERSITY
Abstract: The invention provides bipartite inhibitors of bacterial RNA polymerase having the general structural formula (I): X-?-Y??(I) wherein X is an moiety that binds to the rifamycin binding site of a bacterial RNA polymerase, Y is a moiety that binds to the GE23077 binding site of a bacterial RNA polymerase, and ? is a linker. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.
Type:
Grant
Filed:
August 15, 2016
Date of Patent:
July 3, 2018
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Richard H. Ebright, David Degen, Yu Zhang, Yon Ebright
Abstract: By using the method and equipment according to this invention it is possible to analyze rapidly a large number of microbiological culture samples, or alternatively of liquid phase samples, based on the gases or gaseous compounds released by them. This invention exploits generally a sample line, along which the samples move, and it can be used for the microbial control tasks in hospitals, industry, hygiene and environmental fields. In this system gas is led into the culture vessels during the growth of the microbe, and gases released by the culture or liquids derived from them are collected into the chambers, capsules or equivalents.
Abstract: The invention relates to a polypeptide capable of binding human complement component 5 (C5), said polypeptide comprising the amino acid sequence (SEQ ID NO: 296) [BM]-[L2]-QSX42X43LLX46EAKKLX52X53X54Q wherein [BM] is a C5 binding motif; [L2] is an interconnecting loop; X42 is selected from A and S; X43 is selected from N and E; X46 is selected from A, S and C; X52 is selected from E, N and S; X53 is selected from D, E and S, provided that X53 is not D when X52 is N; and X54 is selected from A and S.
Type:
Grant
Filed:
August 28, 2014
Date of Patent:
June 12, 2018
Assignee:
Swedish Orphan Biovitrum AB (publ)
Inventors:
Joakim Nilsson, Erik Nordling, Patrik Strömberg
Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
Type:
Grant
Filed:
April 28, 2016
Date of Patent:
June 5, 2018
Assignee:
CSL Behring GmbH
Inventors:
Stefan Zeitler, Marc Nolte, Stefan Schulte, Gerhard Dickneite, Ingo Pragst
Abstract: Disclosed herein are a modified sulfamidase, a composition comprising a modified sulfamidase, as well as methods for preparing a modified sulfamidase and therapeutic use of such a sulfamidase. In particular, the present disclosure relates to a modified sulfamidase comprising substantially no epitopes for glycan recognition receptors, thereby enabling transportation of said sulfamidase across the blood brain barrier of a mammal, wherein said sulfamidase has catalytic activity in the brain of said mammal.
Type:
Grant
Filed:
July 22, 2015
Date of Patent:
May 29, 2018
Assignee:
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventors:
Charlotta Berghard, Erik Nordling, Stefan Svensson Gelius, Agneta Tjernberg
Abstract: Provided are: a targeting molecule targeting a target cell which is selected from the group consisting of a stellate cell, a myofibroblast, a cancer-associated fibroblast, a tumor cell and a cell expressing STRA6, said targeting molecule being selected from the group consisting of (1) a peptide containing an amino acid sequence in the cell-binding region of RBP, (2) a variant peptide of the aforesaid peptide (1), said variant peptide having a comparable targetability to peptide (1), and (3) a peptide mimetic having a comparable targetability to peptide (1) or peptide (2); a targeting agent, a carrier, a complex and a medicinal composition each comprising the targeting molecule; a method for treating, examining, diagnosing or monitoring a disease related to the aforesaid target cell; a method for labeling, detecting or imaging the target cell, etc.
Abstract: The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections.
Type:
Grant
Filed:
December 11, 2014
Date of Patent:
May 15, 2018
Assignee:
Northwestern University
Inventors:
Charles N. Rudick, David J. Klumpp, Anthony J. Schaeffer
Abstract: Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Ac?, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition.
Type:
Grant
Filed:
January 21, 2014
Date of Patent:
May 1, 2018
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Abstract: The present invention includes bivalent or multivalent nucleic acid molecules or complexes of nucleic acid molecules having two or more target-specific regions, in which the target-specific regions are complementary to a single target gene at more than one distinct nucleotide site, and/or in which the target regions are complementary to more than one target gene or target sequence. Also included are compositions comprising such nucleic acid molecules and methods of using the same for multivalent RNA interference and the treatment of a variety of diseases and infections.
Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
Type:
Grant
Filed:
January 22, 2016
Date of Patent:
April 24, 2018
Assignee:
Dynavax Technologies Corporation
Inventors:
Gary S. Ott, Robert J. Milley, Robert L. Coffman, Radwan R Kiwan, Holger Kanzler
Abstract: Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently an Auristatin compound. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
Type:
Grant
Filed:
January 19, 2016
Date of Patent:
April 17, 2018
Assignee:
Mersana Therapeutics, Inc.
Inventors:
Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dimitry R. Gumerov
Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
Type:
Grant
Filed:
June 2, 2011
Date of Patent:
April 17, 2018
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
Abstract: Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.
Type:
Grant
Filed:
July 11, 2013
Date of Patent:
April 10, 2018
Assignee:
USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I.
Inventors:
Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Popelova
Abstract: A chimeric protein that is a fusion construct of a series of functional domains is used to deliver a therapeutic agent to a human subject suffering from disease. In some embodiments, the chimeric protein includes a therapeutic region, a transportation region, and a cleavage region disposed between the therapeutic region and the transportation region. The transportation region allows the chimeric protein to be moved across a cellular membrane of an affected cell within the subject. Cleavage of the chimeric protein at the cleavage region once within the cell separates the therapeutic region from the transportation region, enabling the therapeutic region to function normally within the cell. The therapeutic region can be effective in the treatment of, for example, muscular dystrophy, diastrophic dysplasia, malignant melanoma, porphyria, alpha-1 antitrypsin deficiency, Aicardi-Goutieres syndrome, cystic fibrosis, progeria, Marfan syndrome, tuberous sclerosis, adrenoleukodystrophy, and the like.
Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
Type:
Grant
Filed:
October 21, 2014
Date of Patent:
March 27, 2018
Assignee:
Salk Institute for Biological Studies
Inventors:
Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
Abstract: The present invention relates to a process for production of fermentation products, including bioethanol by non-pressurized pre-treatment, enzymatic hydrolysis and fermentation of waste fractions containing mono- and/or polysaccharides, having a relatively high dry matter content. The process in its entirety, i.e. from non-pressurized pre-treatment over enzymatic hydrolysis and fermentation to sorting of fermentable and non-fermentable solids can be processed at a relatively high dry matter content in a single vessel or similar device using free fall mixing for the mechanical processing of the waste fraction.
Type:
Grant
Filed:
September 29, 2006
Date of Patent:
March 13, 2018
Assignee:
RENESCIENCE A/S
Inventors:
Nanna Dreyer Nørholm, Jan Larsen, Frank Krogh Iversen
Abstract: The invention relates to a method for selecting proteins stable in non-standard physicochemical conditions (temperature, pressure, pH, osmolarity, salinity, solvent, etc.) comprising the expression, in an extremophilic microorganism, of variants of the protein of interest in the form of a fusion protein with a reporter protein which is stable in extreme conditions and acts as a selection marker.